by Elec23 | Jun 19, 2026 | News&events, VisMederi
From kit design and manufacturing to biological sample management and laboratory testing, VisMederi offers a fully integrated solution for clinical trials and research programs worldwide. VisMederi, a company specialized in vaccine evaluation through advanced...
by Elec23 | Jun 18, 2026 | News&events, VisMederi
VisMederi and CEVAC, a Belgian vaccine research center comprising a Clinical Trial Unit and an Immunomonitoring Laboratory, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in vaccine clinical trials, a core area of expertise for both...
by Elec23 | Mar 11, 2026 | News&events, VisMederi
VisMederi highlighted its collaboration with Sumitomo Pharma Co., Ltd. and Japan’s National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in the European Phase 1 clinical programme evaluating a universal influenza vaccine candidate formulated with...
by Elec23 | Mar 3, 2026 | News&events, VisMederi
VisMederi is a partner in NOFLU, a European consortium selected by the European Union to support the early clinical development of a next-generation pandemic influenza vaccine. The project is coordinated by NIVI Development, the development arm of the Novo Nordisk...
by Elec23 | Jan 23, 2026 | News&events, VisMederi
VisMederi emphasizes the importance of its role within Coalition for Epidemic Preparedness Innovations (CEPI)’s Centralized Laboratory Network, the world’s largest network dedicated to standardising the assessment of epidemic and pandemic vaccine candidates. In the...
